| Literature DB >> 34850398 |
Jennifer Cable1, Duanqing Pei2,3,4, Lola M Reid5, Xin Wei Wang6, Sonam Bhatia7, Panagiotis Karras8, Jan Joseph Melenhorst9, Markus Grompe10, Justin D Lathia11, Erwei Song12,13, Calvin J Kuo14, Ning Zhang15, Richard M White16, Stephanie Ky Ma17, Lichun Ma18, Y Rebecca Chin19, Michael M Shen20, Irene Oi Lin Ng21, Klaus H Kaestner22, Lei Zhou23, Shaheen Sikandar24, Clemens A Schmitt25, Wei Guo26, Carmen Chak-Lui Wong21, Junfang Ji27, Dean G Tang28, Anna Dubrovska29,30,31,32, Chunzhang Yang33, Wolf R Wiedemeyer34, Irving L Weissman35.
Abstract
The test for the cancer stem cell (CSC) hypothesis is to find a target expressed on all, and only CSCs in a patient tumor, then eliminate all cells with that target that eliminates the cancer. That test has not yet been achieved, but CSC diagnostics and targets found on CSCs and some other cells have resulted in a few clinically relevant therapies. However, it has become apparent that eliminating the subset of tumor cells characterized by self-renewal properties is essential for long-term tumor control. CSCs are able to regenerate and initiate tumor growth, recapitulating the heterogeneity present in the tumor before treatment. As great progress has been made in identifying and elucidating the biology of CSCs as well as their interactions with the tumor microenvironment, the time seems ripe for novel therapeutic strategies that target CSCs to find clinical applicability. On May 19-21, 2021, researchers in cancer stem cells met virtually for the Keystone eSymposium "Cancer Stem Cells: Advances in Biology and Clinical Translation" to discuss recent advances in the understanding of CSCs as well as clinical efforts to target these populations.Entities:
Keywords: cancer stem cell; hepatocellular carcinoma; organoids; pluripotent; progenitors; stemness; tumor heterogeneity; tumorigenesis
Mesh：
Substances：
Year: 2021 PMID： 34850398 PMCID： PMC9153245 DOI： 10.1111/nyas.14719
Source DB: PubMed Journal: Ann N Y Acad Sci ISSN： 0077-8923 Impact factor: 6.499